have high on-treatment platelet reactivity (HTPR) are at increased risk of subsequent ischemic events, including ST. [1] [2] [3] [4] [5] [6] Newer and stronger P2Y 12 inhibitors such as prasugrel and ticagrelor are, on a population basis, more effective at reducing risk of ischemic complications but are also associated with increased risk of bleeding, although it is unclear whether this risk can be predicted in an individual by the level of response to these agents. 7, 8 In addition to this, there is also evidence that some patients do not have a therapeutic response to these agents. 9, 10 Given the consequences of a subtherapeutic response to clopidogrel (or other P2Y 12 inhibitors), and the potential to establish a "therapeutic window" for these agents which minimizes the risk of ischemic or bleeding events, it may be suboptimal that there is no routine testing of the individual response to them. This is the case for 2 main reasons. Firstly, previous randomized trials of tailored P2Y 12 inhibitor therapy in DES patients exhibiting low response to clopidogrel using the VerifyNow point of care (POC) assay have been negative. [11] [12] [13] In fact, recent data call into question the appropriateness of VerifyNow for this task. 14, 15 Secondly, aside from VerifyNow, there is no other cheap, quick, accurate, and genuinely POC platelet function test (PFT). Specifically, no POC test has adequate clinical outcomes data to justify a robust and clinically meaningful cut off value that describes response in terms of risk of ischemic or bleeding events.
Thrombelastography (TEG) is an ex vivo whole blood clotting assay. 16 Using agonists that predominantly stimulate plateletinduced clotting, TEG 5000 represents a well established PFT that correlates with aggregometry. 4, [17] [18] [19] [20] [21] [22] [23] However, TEG 5000 requires specialist training and is not POC. The recently developed TEG 6s system (Haemonetics Corp, Massachusetts, USA) represents a genuinely near patient and user-friendly test that has shown promise. 24, 25 The aims of these experiments were as follows. Firstly, to validate the ability of TEG 6s to detect individualized response of patients and volunteers to clopidogrel, using TEG 5000 as a ref-
erence. Secondly, to test a novel parameter, area under the curve at 15 minutes (AUC15), in the TEG 6s assay in order to determine whether it is possible to provide an accurate assessment of the response to clopidogrel significantly quicker than by conventional TEG 6s test. 
| ME THODS

| Ethical approval
| Study population
This was a single center, prospective, observational study conducted at University Hospital Southampton NHS Foundation Trust. The following study groups were recruited: (1) group 1-12 healthy volunteers, who received clopidogrel 600 milligrams (mg) once and had blood sampling at baseline (predrug) then 2, 6, and 24 hours after clopidogrel ingestion; (2) group 2-12 patients with suspected non-ST elevation myocardial infarction (NSTEMI), who received clopidogrel 600 mg and underwent blood sampling at baseline (predrug) then 2, 6-18, and 24 hours after clopidogrel ingestion; (3) 1 healthy volunteer, who received clopidogrel 600 mg on 5 separate occasions, at least 2 weeks apart, and underwent blood sampling at baseline (predrug) and 6 hours after clopidogrel ingestion, to assess for intraindividual reproducibility. Inclusion and exclusion criteria are shown as Table S1 .
| Blood sampling
At each sampling interval, venesection was performed from the antecubital fossa using a BD Vacutainer ® 21G needle and tourniquet. The first 2 mL of blood were discarded. Blood was then drawn firstly into a 2.7 mL Sodium Citrate BD Vacutainer ® for thrombin channel analysis. For TEG 5000 platelet mapping channels and all TEG 6s channels blood was collected into 4.0 mL Sodium Heparin BD Vacutainers ® . The blood bottles were inverted an appropriate 
| Thrombelastography
| TEG 5000 system
The TEG 5000 device is a platelet function analyser, which utilizes the modified TEG platelet mapping system to determine individual response to APT. This method has been described in detail previously. 16 In brief, 3 agonist channels were run using: (1) 
| TEG 6s system
Thrombelastography 6s is a new, automated PFT which utilizes microfluidic cartridges to produce a value of the clot strength, using the same parameters as TEG 5000. To determine individual response to clopidogrel, the ADP platelet mapping microfluidic cartridge was Thrombelastography 6s determines clot viscoelasticity using the resonance method ( Figure S1 ). A cartridge is inserted into the device and an unmetered amount of heparinized blood (~300 μL) is added. The platelet mapping cartridges contain channels, which are preloaded with the appropriate reagents. Following the initiation of sampling, the device draws a controlled volume of blood through to each channel, which mixes with the reagents and excess blood then passes to a waste chamber. Each channel is then exposed to a fixed vibration frequency of between (20-500 Hz), the resultant motion of the blood meniscus is measured by an LED detector. The device determines the resonant frequencies of this movement using a Fast Fourier Transform, producing a TEG readout using a mapping function. Stronger clots have higher resonant frequencies and therefore produce a TEG trace of greater amplitude.
| Area under the curve at 15 minutes and short thrombelastography
Traditionally, antiplatelet therapy response has been determined from the maximum amplitude (MA) of the TEG trace, which represents the strength of final clot. However, even using TEG 6s, the MA is often not reached until >25 minutes for ADP and >45 minutes for thrombin channels, respectively. This group has developed and validated a TEG modification known as "Short-TEG" (sTEG) using TEG 5000. and represents the primary phase of plasma clotting and inhibitor activity. We have applied the AUC15 test to TEG 6s for the first time.
| Statistical analysis
Continuous variables are presented as mean and standard deviation (SD) of the mean if normally distributed, or as median and interquartile range (IQR) if not. Normality of data was tested using the ShapiroWilk test. Categorical variables were presented as frequencies with Outputs of the 2 TEG methods allowed direct comparison between devices. Correlation between continuous variables was assessed using
Pearson`s correlation for parametric data and Spearman's rank correlation for nonparametric data. The level of agreement between the data derived from 2 devices was assessed using Bland-Altman analysis.
| RE SULTS
| Study participants and baseline characteristics
Twelve healthy volunteers (Group 1) and 12 patients (Group 2) were recruited, as well as 1 volunteer for the reproducibility experiment.
All subjects received a loading dose of 600 mg of clopidogrel (except 3 of Group 1 who received 450 mg due to dispensing error).
One patient originally recruited to Group 2 was withdrawn due to split dose administration of clopidogrel. Baseline demographics for all 3 groups are presented in Table 1 .
| Validation of TEG 6s
| Precision testing
The MA results obtained from healthy volunteers and patients at different time points are expressed as median, IQR, and IQR/median ratio to allow direct comparison. TEG 6s demonstrated very little inter-individual variation (groups 1 and 2) across a large number of samples and a high level of intra-individual reproducibility (1 healthy volunteer) ( Table 2 ).
The comparison of variation across all 3 groups and time points (means and 95% CI) is presented in Figure 2 . The values in the thrombin channel for TEG 5000 remain static, for TEG 6s the difference reach statistical significance (P < .05) at 6 hours in group 1, at 24 hours in group 2, and at 6 hours for 1 healthy volunteer. The ADP channel shows that both devices are able to detect platelet inhibitory effects of clopidogrel in a time-dependent manner. Details on comparison expressed as P values for TEG 5000 and TEG 6s between all time points for each device separately as well as a direct comparison between 2 devices at any time point are available as Tables S2 and S3, respectively.
| Correlation between TEG 5000 MA and TEG 6s MA
As assessed by Spearman`s rank correlation for all groups combined, MAs in the ADP channel showed the strongest correlation (N = 100, correlation coefficient R = .821, R 2 = 0.674, P < .001), followed by thrombin (N = 98, correlation coefficient R = .494, R 2 = 0.244, P < .001) (Figure 3 ). Details of correlation for each group and channel separately are available as a Figure S2 .
| Agreement between TEG 5000 MA and TEG 6s MA
The agreement between MAs produced by TEG 5000 and TEG 6s for individual agonist-activated channels for all groups was assessed using the Bland-Altman analysis (Figure 4 ). Data for groups 1, 2, and 3 separately are available as a Figure S3 . 3.3 | AUC15 using TEG 6s
| Ability of AUC15 to detect a change in clotting
Results of TEG 5000 AUC15 and TEG 6s AUC15 show similar pattern of change across all study groups ( Figure S4 ). Values for both devices in thrombin channel as expected remain static and are higher than in ADP channel.
| Time saved
As shown in Table 3 a mean of 5.5 minutes can be saved in thrombin channel and 13.32 minutes in ADP channel when using TEG 6s AUC15 to produce a result describing individual response using MA as the reference.
| Correlation between TEG 6s MA and TEG 6s AUC15
For all groups and participants combined, correlation between TEG 6s MA and AUC15 in both thrombin (N = 102, correlation coefficient R = .867, R 2 = 0.752, P < .001) and ADP channels (N = 95, correlation coefficient R = .936, R 2 = 0.876, P < .001) were very strong ( Figure 5 ).
| Correlation and agreement between TEG 5000 AUC15 and TEG 6s AUC15
Correlation and agreement between TEG 5000 AUC15 and TEG 6s AUC15 are presented in Figures S5 and S6 . clotting renders the concept of tailored therapy of these agents both logical and attractive. Specifically, concern about the potential for some individuals to exhibit a "low" response, which would put them at risk of ischemic events and some to exhibit an exagger- This study has several limitations. Firstly, this is a single center study. Secondly, the number of participants in each group is low, although consistent with previous studies. Specifically, the TEG 5000 results described here are reproducible with other previous experiments, thus allowing a considerable degree of confidence that our reference is robust. Thirdly, although the results of this study are encouraging, comparing 2 devices is always associated with the uncertainty about interpretation regarding which is correct when they F I G U R E 5 Scatter plots showing correlation between TEG 6s MA and AUC15 in thrombin (A) and ADP (B) channels for all groups and time points combined. ADP, adenosine diphosphate; MA, maximum amplitude; TEG, thrombelastography disagree. Finally, it is a mechanistic study with no clinical outcome data regarding potential ischemic/bleeding benefits to individual participants.
| D ISCUSS I ON
In conclusion, TEG 6s is a rapid and easy to use POC test whose reproducibility and ability to detect responses of volunteers and patients to clopidogrel is satisfactory using TEG 5000 as a reference. A novel parameter, AUC15, offers an even more rapid test for individual response to P2Y 12 therapy. TEG 6s may be a candidate as an appropriate test for personalized P2Y 12 strategy trials.
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